Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05166577
Title Nanatinostat Plus Valganciclovir in Patients With Advanced EBV+ Solid Tumors, and in Combination With Pembrolizumab in EBV+ RM-NPC
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Viracta Therapeutics, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | CAN | AUS


No variant requirements are available.